VYNE Therapeutics (VYNE) shares were edging higher Monday morning after the biopharmaceutical company reported "positive" phase 1a results for its novel BD2-selective BET inhibitor VYN202.
The company said the results support the inhibitor's potential as a new oral treatment for various immune-mediated disorders.
VYN202 showed a favorable safety and tolerability profile without any drug-related adverse events in the phase 1a trial as well as "robust pharmacodynamic activity," VYNE said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。